📬 Breast Cancer Intelligence Digest — Week 2026-W27

A wave of FDA actions reshaped first-line TNBC and HR+/HER2+ maintenance therapy, while DAPHNe 5-year data and SACI-IO HR+ refined de-escalation and biomarker-driven strategies.

⚡ TL;DR

📄 Publications

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. — SG+pembrolizumab did not significantly improve PFS vs SG (8.4 vs 6.7 months; HR 0.76, p=0.12)
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial. — With median 5.2-year follow-up, 5-year EFS was 99%, 5-year distant RFI 100%, and 5-year OS 99%
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study. — Among pCR patients, clinical node-positive/low-TIL tumors had 5-year distant relapse-free survival of 83.4% and overall survival of 85.8%
Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study. — In H1 cancers (n=1,106), 3-year IDFS did not differ between AC-T and TC (95.9% v 95.9%; adjusted HR 1.14)
Spatial analyses implicate high stromal tumour-infiltrating CD8+ lymphocytes as a negative predictive marker for chemotherapy in estrogen receptor-positive breast cancer. — In an Intermediate RS cohort treated with chemotherapy, higher stromal CD8+ TIL density was associated with poor outcome (ΔLR-χ2: 6.79, p=0.009)

🐦 Twitter / 🦋 Bluesky

DAPHNe 5-year results support ctDNA-guided de-escalation of neoadjuvant THP in HER2+ disease — Among 98 patients treated with neoadjuvant THP ×4 and no further chemo if pCR, no distant recurrences occurred and 5-year EFS was 99%
FDA approves palbociclib maintenance in HR+/HER2+ metastatic breast cancer based on PATINA — PATINA showed median PFS 44.3 vs 29.1 months for adding a CDK4/6i to anti-HER2 + endocrine therapy after induction
GAMBIT: pCR does not always mean cure in TNBC — In cN+ disease with low TILs (<30%), 5-year DRFS was 83.4% and OS 85.8% despite pCR, with isolated CNS relapses
FDA approves first-line sacituzumab govitecan, alone or with pembrolizumab, in metastatic TNBC — SG ± pembro approved in 1L mTNBC: PD-L1-negative mPFS 9.7 vs 6.9 months (HR 0.62), PD-L1-positive mPFS 11.2 vs 7.8 months (HR 0.65)
European Commission approves first-line sacituzumab govitecan for PD-(L)1-ineligible metastatic TNBC — EC approved SG as the first ADC and first new 1L option in over 20 years for previously untreated mTNBC not eligible for PD-(L)1 inhibitors, with a 38% reduction in risk of progression or death

Full details below ↓

📄 What's Being Published

Manuscripts:

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. — Garrido-Castro A C et al., Ann Oncol

In this randomized phase II trial, SG plus pembrolizumab did not significantly improve PFS compared to SG alone (8.4 vs 6.7 months; HR 0.76, 95% CI 0.48–1.19, p=0.12). Among PD-L1-positive patients, median PFS was 11.1 vs 5.6 months (HR 0.51, 95% CI 0.24–1.12, p=0.09) and median OS was 18.5 vs 12.5 months (HR 0.59, 95% CI 0.18–1.98, p=0.39) with the combination. TROP2 expression and TILs were not associated with outcomes; higher ctDNA fraction and PIK3CA mutations were associated with worse PFS.

Clinical bottom line: Adding pembrolizumab to sacituzumab govitecan did not improve outcomes in unselected HR+/HER2- MBC, but a numerical signal in PD-L1-positive disease supports biomarker-selected testing.

Read full article →

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial. — Tarantino Paolo et al., JAMA Oncol

With a median 5.2-year follow-up, the 5-year event-free survival was 99% (95% CI, 97%–100%), the 5-year distant RFI was 100% (95% CI, 100%–100%), and the 5-year overall survival was 99% (95% CI, 97%–100%). After neoadjuvant therapy, ctDNA clearance occurred in 49 of 51 patients (96.1%), with only 2 individuals (3.9%) remaining ctDNA-positive preoperatively.

Clinical bottom line: Abbreviated neoadjuvant THP delivered excellent 5-year outcomes with near-universal ctDNA clearance, supporting ctDNA-guided de-escalation in selected stage II–III HER2-positive breast cancer.

Read full article →

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study. — Massa Davide et al., Nat Commun

Among TNBC patients who achieved pCR, those with clinical node-positive/low-TIL tumors experienced substantially worse outcomes, with five-year distant relapse-free survival of 83.4% and overall survival of 85.8%. In this high-risk subgroup, the five-year cumulative incidence of CNS relapse reached 7.5%, including 6.9% presenting as isolated CNS relapse.

Clinical bottom line: Even after pCR in TNBC, clinical nodal status and stromal TILs identify a high-risk subgroup with substantial distant and CNS relapse, supporting risk-adapted surveillance and CNS-directed trial design.

Read full article →

Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study. — O'Shaughnessy Joyce et al., JCO Precis Oncol

Among patients with H1 cancers (n=1,106), 3-year IDFS did not differ between AC-T and TC (95.9% v 95.9%; adjusted HR 1.14 [95% CI, 0.64 to 2.06]; P=.70). Among patients with H2 cancers (n=153), AC-T significantly improved 3-year IDFS versus TC (100% v 94.8%; adjusted HR 0.10 [95% CI, 0.01 to 0.75]; absolute benefit 5.2%; P=.025).

Clinical bottom line: MammaPrint H2 tumors derive clinically meaningful benefit from anthracyclines while H1 tumors do not, supporting genomic selection of chemotherapy regimens in HR+/HER2- early breast cancer.

Read full article →

Spatial analyses implicate high stromal tumour-infiltrating CD8+ lymphocytes as a negative predictive marker for chemotherapy in estrogen receptor-positive breast cancer. — Kinsella Zak et al., Nat Commun

In an intermediate recurrence score cohort treated with chemotherapy, higher stromal CD8+ TIL density was associated with poor outcome (ΔLR-χ2: 6.79, p=0.009).

Clinical bottom line: High stromal CD8+ TIL density predicts poor chemotherapy outcome in intermediate-risk ER+/HER2- breast cancer, proposing sTIL CD8+ density as a candidate biomarker for treatment decisions.

Read full article →

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial. — De Caluwé Alex et al., Nat Med

In the ITT population, the primary endpoint of residual cancer burden 0/1 rate was 35.4% with No_ICI, 45.1% with Single_ICI, and 47.9% with Double_ICI, without statistically significant differences. Among PD-L1-negative tumors (n=91), pCR rates were 3.4%, 28.1%, and 30.0%, respectively.

Clinical bottom line: Immune-modulating SBRT plus anti-PD-L1 may convert immune-cold ER+/HER2- breast cancer into inflamed tumors and improve pCR, particularly in PD-L1-negative disease.

Read full article →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

DAPHNe 5-year results support ctDNA-guided de-escalation of neoadjuvant THP in HER2+ disease

Among 98 patients treated with neoadjuvant THP ×4 and no further chemotherapy if pCR was achieved, no distant recurrences occurred and 5-year EFS was 99%. ctDNA clearance reached 96%, further supporting de-escalation strategies in selected patients. The open debate centers on whether ultrasensitive ctDNA monitoring can identify which low-risk HER2+ patients are safely cured with abbreviated THP ahead of CompassHER2-pCR.

Discussed by: @PTarantinoMD, @Dr_ElvinaA, @FatihGurlerMD

→ View representative tweet

FDA approves palbociclib maintenance in HR+/HER2+ metastatic breast cancer based on PATINA

The phase 3 PATINA trial demonstrated a significant PFS benefit for adding a CDK4/6 inhibitor to anti-HER2 plus endocrine therapy after induction, with median PFS of 44.3 vs 29.1 months — a greater than 15-month gain — and an HR of 0.76 versus standard anti-HER2 therapy plus endocrine therapy alone. The approval prompted clinicians to debate whether PATINA establishes CDK4/6 inhibition as a new maintenance standard across all HR+/HER2+ metastatic patients regardless of induction regimen.

Discussed by: @OncBrothers, @Dr_ElvinaA, @hoperugo

→ View representative tweet

GAMBIT: pCR does not always mean cure in TNBC

Across 2,457 patients evaluated in the GAMBIT study, 1,192 achieved pCR; however, in those with cN+ disease and low TILs (<30%), 5-year DRFS was 83.4% and OS was 85.8% despite pCR, with approximately 4× higher relapse risk and approximately 6× higher mortality risk versus lower-risk subgroups. A substantial proportion of recurrences in this subgroup were isolated CNS metastases, prompting specialists to ask whether baseline nodal status and TILs should trigger CNS-directed surveillance or treatment escalation even after pCR in TNBC.

Discussed by: @dr_yakupergun, @K_Yadavir

→ View representative tweet

FDA approves first-line sacituzumab govitecan, alone or with pembrolizumab, in metastatic TNBC

Sacituzumab govitecan received FDA approval for first-line metastatic TNBC both as monotherapy for patients ineligible for PD-1/PD-L1 inhibitors and in combination with pembrolizumab for PD-L1-positive disease (CPS ≥10). Efficacy data showed mPFS of 9.7 vs 6.9 months (HR: 0.62) in PD-L1-negative patients and mPFS of 11.2 vs 7.8 months (HR: 0.65) in PD-L1-positive patients. With three TROP2 ADCs converging on frontline TNBC, clinicians are weighing how to differentiate among them by PD-L1 stratum.

Discussed by: @ErikaHamilton9, @AnisToumeh, @hoperugo

→ View representative tweet

European Commission approves first-line sacituzumab govitecan for PD-(L)1-ineligible metastatic TNBC

The European Commission approved sacituzumab govitecan as the first ADC — and the first new treatment option in over 20 years in Europe — for patients with previously untreated metastatic TNBC who are not candidates for PD-(L)1 inhibitors. The approval was based on the ASCENT-03 trial, which showed a highly significant improvement in progression-free survival compared with chemotherapy and a 38% reduction in risk of progression or death. Oncologists are considering how this first-line SG approval will reshape options for TNBC patients who cannot receive immunotherapy.

Discussed by: @nataliagandur, @OncoAlert

→ View representative tweet

SACI-IO HR+: ADC plus immunotherapy fails overall but signals in PD-L1-positive HR+/HER2- disease

Adding pembrolizumab to sacituzumab govitecan did not significantly improve PFS versus SG alone (8.4 vs 6.7 months), yet PD-L1-positive patients showed numerical improvements with the combination: median PFS 11.1 vs 5.6 months and median OS 18.5 vs 12.5 months. Clinicians are examining whether PD-L1 status, PIK3CA alterations, or plasma biomarkers can select HR+/HER2- patients who derive benefit from ADC plus immunotherapy combinations.

Discussed by: @Dr_Oncologista, @nataliagandur

→ View representative tweet

Neo-CheckRay: stereotactic radiation primes immunotherapy in immune-cold ER+/HER2- breast cancer

In 147 high-risk ER+/HER2- patients on the Neo-CheckRay trial, pCR in the ITT population rose from 16.7% to 29.4% to 33.3% across arms (P=0.059), with a particularly marked effect in PD-L1-negative tumors, where pCR rates were 3.4%, 28.1%, and 30.0% with progressive addition of immunotherapy. Oncologists are debating whether iSBRT could serve as the partner that makes checkpoint blockade effective in immune-cold ER+/HER2- disease.

Discussed by: @DrRishabhOnco, @OncoAlert

→ View representative tweet

🔥 Top Ranked Tweets

OncoAlert @OncoAlert

RT @OncoAlert: News From Industry
ASCENT03 Update
Source GILEAD

The European Commission has approved sacituzumab govitecan as the first antibody-drug conjugate and first new treatment option in over 20 years for patients with previously untreated metastatic triple-negative #BreastCancer who are not eligible for PD-(L)1 inhibitors. The approval, based on the ASCENT-03 trial, showed a highly significant improvement in progression-free survival compared with chemotherapy.

https://t.co/JyRTZnK67K

Pinging faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H

@nataliagandur @acampsmalea @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @GaiaGriguolo
@MarioBalsaMD

🔖 5 ❤️ 37 🔁 23 👁 4,651